- Recommendation ID
- TA220/1
- Question
- NICE highlighted the importance of collecting further data within registries of patients receiving biological treatments for psoriatic arthritis to obtain information on long-term outcomes, including adverse events.
- Any explanatory notes
(if applicable) - None.
Source guidance details
- Comes from guidance
- Golimumab for the treatment of psoriatic arthritis
- Number
- TA220
- Date issued
- April 2011
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |